Sökning: WFRF:(Moysich Kirsten B) > Association Between...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07084naa a2201213 4500 | |
001 | oai:lup.lub.lu.se:63c9393a-89ed-4178-8180-7aabcf107793 | |
003 | SwePub | |
008 | 160401s2012 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/23488682 URI |
024 | 7 | a https://doi.org/10.1001/jama.2012.202 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Bolton, Kelly L.4 aut |
245 | 1 0 | a Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer |
264 | 1 | b American Medical Association (AMA),c 2012 |
520 | a Context Approximately 10% of women with invasive epithelial ovarian cancer (EOC) carry deleterious germline mutations in BRCA1 or BRCA2. A recent article suggested that BRCA2-related EOC was associated with an improved prognosis, but the effect of BRCA1 remains unclear. Objective To characterize the survival of BRCA carriers with EOC compared with noncarriers and to determine whether BRCA1 and BRCA2 carriers show similar survival patterns. Design, Setting, and Participants A pooled analysis of 26 observational studies on the survival of women with ovarian cancer, which included data from 1213 EOC cases with pathogenic germline mutations in BRCA1 (n=909) or BRCA2 (n=304) and from 2666 noncarriers recruited and followed up at variable times between 1987 and 2010 (the median year of diagnosis was 1998). Main Outcome Measure Five-year overall mortality. Results The 5-year overall survival was 36% (95% CI, 34%-38%) for noncarriers, 44% (95% CI, 40%-48%) for BRCA1 carriers, and 52% (95% CI, 46%-58%) for BRCA2 carriers. After adjusting for study and year of diagnosis, BRCA1 and BRCA2 mutation carriers showed a more favorable survival than noncarriers (for BRCA1: hazard ratio [HR], 0.78; 95% CI, 0.68-0.89; P<.001; and for BRCA2: HR, 0.61; 95% CI, 0.50-0.76; P<.001). These survival differences remained after additional adjustment for stage, grade, histology, and age at diagnosis (for BRCA1: HR, 0.73; 95% CI, 0.64-0.84; P<.001; and for BRCA2: HR, 0.49; 95% CI, 0.39-0.61; P<.001). The BRCA1 HR estimate was significantly different from the HR estimated in the adjusted model (P for heterogeneity=.003). Conclusion Among patients with invasive EOC, having a germline mutation in BRCA1 or BRCA2 was associated with improved 5-year overall survival. BRCA2 carriers had the best prognosis. JAMA. 2012;307(4):382-390 | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Medicinsk genetik0 (SwePub)301072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Medical Genetics0 (SwePub)301072 hsv//eng |
700 | 1 | a Chenevix-Trench, Georgia4 aut |
700 | 1 | a Goh, Cindy4 aut |
700 | 1 | a Sadetzki, Siegal4 aut |
700 | 1 | a Ramus, Susan J.4 aut |
700 | 1 | a Karlan, Beth Y.4 aut |
700 | 1 | a Lambrechts, Diether4 aut |
700 | 1 | a Despierre, Evelyn4 aut |
700 | 1 | a Barrowdale, Daniel4 aut |
700 | 1 | a McGuffog, Lesley4 aut |
700 | 1 | a Healey, Sue4 aut |
700 | 1 | a Easton, Douglas F.4 aut |
700 | 1 | a Sinilnikova, Olga4 aut |
700 | 1 | a Benitez, Javier4 aut |
700 | 1 | a Garcia, Maria J.4 aut |
700 | 1 | a Neuhausen, Susan4 aut |
700 | 1 | a Gail, Mitchell H.4 aut |
700 | 1 | a Hartge, Patricia4 aut |
700 | 1 | a Peock, Susan4 aut |
700 | 1 | a Frost, Debra4 aut |
700 | 1 | a Evans, Gareth4 aut |
700 | 1 | a Eeles, Rosalind4 aut |
700 | 1 | a Godwin, Andrew K.4 aut |
700 | 1 | a Daly, Mary B.4 aut |
700 | 1 | a Kwong, Ava4 aut |
700 | 1 | a Ma, Edmond S. K.4 aut |
700 | 1 | a Lazaro, Conxi4 aut |
700 | 1 | a Blanco, Ignacio4 aut |
700 | 1 | a Montagna, Marco4 aut |
700 | 1 | a D'Andrea, Emma4 aut |
700 | 1 | a Nicoletto, Maria Ornella4 aut |
700 | 1 | a Johnatty, Sharon E.4 aut |
700 | 1 | a Krueger, Susanne4 aut |
700 | 1 | a Jensen, Allan4 aut |
700 | 1 | a Hogdall, Estrid4 aut |
700 | 1 | a Goode, Ellen L.4 aut |
700 | 1 | a Fridley, Brooke L.4 aut |
700 | 1 | a Loud, Jennifer T.4 aut |
700 | 1 | a Greene, Mark H.4 aut |
700 | 1 | a Mai, Phuong L.4 aut |
700 | 1 | a Chetrit, Angela4 aut |
700 | 1 | a Lubin, Flora4 aut |
700 | 1 | a Hirsh-Yechezkel, Galit4 aut |
700 | 1 | a Glendon, Gord4 aut |
700 | 1 | a Andrulis, Irene L.4 aut |
700 | 1 | a Toland, Amanda E.4 aut |
700 | 1 | a Senter, Leigha4 aut |
700 | 1 | a Gore, Martin E.4 aut |
700 | 1 | a Gourley, Charlie4 aut |
700 | 1 | a Michie, Caroline O.4 aut |
700 | 1 | a Song, Honglin4 aut |
700 | 1 | a Tyrer, Jonathan4 aut |
700 | 1 | a Whittemore, Alice S.4 aut |
700 | 1 | a McGuire, Valerie4 aut |
700 | 1 | a Sieh, Weiva4 aut |
700 | 1 | a Kristoffersson, Ulfu Lund University,Lunds universitet,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Genetics,Department of Laboratory Medicine,Faculty of Medicine4 aut0 (Swepub:lu)kgen-ukr |
700 | 1 | a Olsson, Håkanu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-hol |
700 | 1 | a Borg, Åkeu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-abo |
700 | 1 | a Levine, Douglas A.4 aut |
700 | 1 | a Steele, Linda4 aut |
700 | 1 | a Beattie, Mary S.4 aut |
700 | 1 | a Chan, Salina4 aut |
700 | 1 | a Nussbaum, Robert L.4 aut |
700 | 1 | a Moysich, Kirsten B.4 aut |
700 | 1 | a Gross, Jenny4 aut |
700 | 1 | a Cass, Ilana4 aut |
700 | 1 | a Walsh, Christine4 aut |
700 | 1 | a Li, Andrew J.4 aut |
700 | 1 | a Leuchter, Ronald4 aut |
700 | 1 | a Gordon, Ora4 aut |
700 | 1 | a Garcia-Closas, Montserrat4 aut |
700 | 1 | a Gayther, Simon A.4 aut |
700 | 1 | a Chanock, Stephen J.4 aut |
700 | 1 | a Antoniou, Antonis C.4 aut |
700 | 1 | a Pharoah, Paul D. P.4 aut |
710 | 2 | a Avdelningen för klinisk genetikb Institutionen för laboratoriemedicin4 org |
773 | 0 | t JAMA: The Journal of the American Medical Associationd : American Medical Association (AMA)g 307:4, s. 382-390q 307:4<382-390x 1538-3598 |
773 | 0 | t JAMAd : American Medical Association (AMA)g 307:4, s. 382-390q 307:4<382-390x 0098-7484 |
856 | 4 | u http://dx.doi.org/10.1001/jama.2012.20y FULLTEXT |
856 | 4 | u https://jamanetwork.com/journals/jama/articlepdf/1104901/joc15157_382_390.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/2348868 |
856 | 4 8 | u https://doi.org/10.1001/jama.2012.20 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.